世界の呼吸器系抗ウイルス薬市場 – 業界動向と2029年までの予測

市場分析と規模                              

人々のウイルス性呼吸器感染症の数は劇的に増加しています。医療訪問と入院の増加により、社会のコストは大幅に上昇しています。200 種類のウイルス性呼吸器病原体のうち、インフルエンザと RS ウイルス (RSV) は最も重要なウイルス性病原体です。抗ウイルス薬は、さまざまな病気の予防と治療に不可欠です。抗ウイルス治療薬は、高齢者のインフルエンザ予防における予防接種の補助として伝統的に使用されてきました。呼吸器ウイルス感染症の治療には、承認されている薬のクラスがいくつかあります。ヌクレオシド類似体、ノイラミニダーゼ阻害剤、イオンチャネル遮断薬、融合タンパク質阻害剤はほんの一例です。アマンタジン、オセルタミビル、リマンタジン、リバビリン、ザナミビルは、最も一般的に処方される抗ウイルス薬の一部です。

Data Bridge Market Researchは、呼吸器系抗ウイルス薬市場は2021年に544億米ドルと評価され、2029年までに780.2億米ドルに達し、2022年から2029年の予測期間中に4.61%のCAGRを記録すると分析しています。市場価値、成長率、市場セグメント、地理的範囲、市場プレーヤー、市場シナリオなどの市場洞察に加えて、Data Bridge Market Researchチームがまとめた市場レポートには、詳細な専門家分析、患者の疫学、パイプライン分析、価格分析、規制枠組みも含まれています。

レポートの範囲と市場セグメンテーション

Market Definition

Antiviral drugs are medicines used to treat viral illnesses, including HIV, hepatitis, herpes, and influenza. Vaccines are used to give antiviral medications. Antiviral medications are also used for specific viral infections, except for a handful that work against a wide spectrum of viruses. Protease inhibitors, reverse transcriptase inhibitors (NRTIs and NNRTIs), neuraminidase inhibitors, and DNA polymerase inhibitors are forms of antiviral drugs available in the market.

Respiratory Antiviral Drugs Market Dynamics

Drivers

• Rise in the prevalence of respiratory viral diseases

The surging prevalence of respiratory viral illnesses such as influenza, bronchiolitis, and others is a major factor driving the respiratory antiviral drugs market's growth rate during the forecast period of 2022-2029. Flu incidence and prevalence are steadily rising over the world. Every year, the flu affects between 5% and 20% of the population in the United States, according to the CDC. In addition, an estimated 200,000 persons are hospitalized in the United States each year owing to flu illness, with 36,000 of them succumbing to flu complications.

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of respiratory antiviral drugs market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

• Increase in the prevalence rate of viral infections and respiratory syncytial virus epidemics

Virus infections and respiratory syncytial virus outbreaks have increased dramatically in recent years, which can be ascribed to changing environmental conditions. Antiviral drugs diminish the capacity of viruses to transmit from cell to cell or person to person while also reducing the length of flu symptoms. Antiviral drugs are prescribed to treat and prevent influenza-like symptoms, viral pneumonia, and respiratory problems. Oseltamivir phosphate (Tamiflu), zanamivir (Relenza), and baloxavir are three of the most commonly prescribed antiviral medications by the Centers for Disease Control and Prevention (CDC) to treat seasonal flu. Hence, the rising prevalence rate of viral infections and respiratory syncytial virus epidemics is expected to enhance the market's growth rate.

Furthermore, the surging geriatric population and sedentary lifestyle of people, including high addiction of smoking will result in the expansion of respiratory antiviral drugs market. Along with this, favorable reimbursement policies will enhance the market's growth rate.

Opportunities

• Increasing number of research and development activities

The market's growth is fueled by an increase in the number of research and development activities. Treatments for respiratory syncytial virus (RSV) infection have shown to be beneficial in the treatment of bronchiolitis. For instance, Ark Biosciences, a biotech company focusing on therapies for viral infections and respiratory disorders, recently announced the phase 2 proof-of-concept study for Ziresovir (AK0529), an antiviral drug, was completed successfully. Bronchiolitis has killed hundreds of thousands of people globally, mostly children under the age of five. As a result, businesses in the respiratory antiviral treatment market are bolstering their research capacity in order to create treatments for infant bronchiolitis. This will provide beneficial opportunities for the respiratory antiviral drugs market growth.

Moreover, the market's growth is fueled by an increase in the number of product launches and emerging new markets. These factors will provide beneficial opportunities for the respiratory antiviral drugs market growth.

Restraints/Challenges

On the other hand, the high cost associated with drug development and distribution will obstruct the market's growth rate. The shortage of healthcare infrastructure in developing economies and the dearth of skilled professionals will challenge the respiratory antiviral drugs market. Additionally, a lack of awareness among people and the availability of generic medications will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.

This respiratory antiviral drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the respiratory antiviral drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Respiratory antiviral drugs market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Respiratory Antiviral Drugs Market

The market for antiviral medications is classified into coronavirus infection, influenza, herpes simplex virus (HSV), hepatitis and other indications. Infectious viruses such as SARS COV-2, Ebola, swine flu, and Zika virus are becoming more common, increasing the demand for effective antiviral medications. In 2021, the Coronavirus infection sector had a market share of over 17% and is expected to increase significantly in the near future. The occurrence of the COVID-19 pandemic, which resulted in a global spike in the number of patients, has provided the segment with unparalleled growth potential.

Furthermore, the respiratory antiviral drugs market is anticipated to rise due to the significant presence of industry participants focused on research and development activities and product launches to battle COVID-19 infection. The US Food and Drug Administration granted Merck and Ridgeback Biotherapeutics emergency use authorization for molnupiravir in December 2021. (FDA). Expanded production and commercialization of these pharmaceuticals to serve a large patient population around the world has boosted category revenue tremendously. As a result, rising demand for antiviral drugs to treat coronavirus infection will boost total market growth.

Recent Development

• In December 2021, Pfizer had received the emergency use authorization from U.S. Food and (FDA) for Novel COVID-19 oral antiviral drug named PAXLOVID. PAXLOVIDTM (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) is approved for emergency use in high-risk adults and children 12 years and older who weigh at least 40 kg.
• In December 2021, Cipla Limited received the Emergency Use Authorization (EUA) permission by Drug Controller General of India (DCGI) to launch oral antiviral COVID drug named Molnupiravir. Molnupiravir is the first oral antiviral authorized by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to treat mild-to-moderate COVID-19 infection in people who are at high risk of developing severe disease.

Global Respiratory Antiviral Drugs Market Scope

The respiratory antiviral drugs market is segmented on the basis of disease type, drug class, type, age group, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Disease Type

• Pneumonia
• Influenza
• Bronchiolitis
• Upper Respiratory Tract Infection
• Others

Drug Class

• Nucleoside Analogs
• Ribavirin
• Aciclovir
• Neuraminidase Inhibitors
• Oseltamivir
• Zanamivir
• Ion Channel Blockers
• Amantadine
• Rimantadine
• Fusion Protein Inhibitors
• Pavilizumab
• Others

Type

• Branded
• Generic

Age Group

• Pediatric
• Adult
• Geriatric

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Respiratory Antiviral Drugs Market Regional Analysis/Insights

The respiratory antiviral drugs market is analysed and market size insights and trends are provided by country, disease type, drug class, type, age group, route of administration, end-users and distribution channel as referenced above.

The countries covered in the respiratory antiviral drugs market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

北米は、市場シェアと市場収益の面で呼吸器系抗ウイルス薬市場を支配しており、予測期間中もその優位性を維持し続けるでしょう。これは、乳幼児の間で呼吸器系ウイルス感染が蔓延しているためであり、医療費の増加により、この地域の市場の成長率がさらに加速するでしょう。さらに、主要な主要企業が新しい技術にますます重点を置くようになると、この地域の市場の成長率がさらに加速するでしょう。

アジア太平洋地域は、高齢者人口の急増により、2022～2029年の予測期間中に最も急速に成長する地域になると予想されています。また、医療インフラの発展と政府の取り組みの増加により、この地域の市場の成長率がさらに加速するでしょう。

レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える国内市場における個別の市場影響要因と規制の変更も提供しています。下流および上流のバリュー チェーン分析、技術動向、ポーターの 5 つの力の分析、ケース スタディなどのデータ ポイントは、個々の国の市場シナリオを予測するために使用される指標の一部です。また、国別データの予測分析を提供する際には、グローバル ブランドの存在と可用性、および地元および国内ブランドとの競争が激しいか少ないために直面​​する課題、国内関税と貿易ルートの影響も考慮されます。    

競争環境と呼吸器系抗ウイルス薬の市場シェア分析

呼吸器系抗ウイルス薬市場の競争状況は、競合他社ごとに詳細を提供します。含まれる詳細には、会社概要、会社の財務状況、生み出される収益、市場の可能性、研究開発への投資、新しい市場への取り組み、世界的なプレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性などがあります。提供されている上記のデータ ポイントは、呼吸器系抗ウイルス薬市場に関連する会社の焦点にのみ関連しています。

呼吸器系抗ウイルス薬市場で活動している主要企業は次のとおりです。

• F.ホフマン・ラ・ロシュ社（スイス）
• マイランNV（米国）
• サノフィ（フランス）
• ファイザー社（米国）
• グラクソ・スミスクライン（英国）
• ノバルティスAG（スイス）
• メルク社（米国）
• アムニール・ファーマシューティカルズLLC（米国）
• アッヴィ社（米国）
• ドクター・レディーズ・ラボラトリーズ社（インド）
• ジダス・カディラ（インド）
• ジョンソン・エンド・ジョンソン プライベート・リミテッド（米国）
• アレンビック・ファーマシューティカルズ・リミテッド（インド）
• ルピナス（インド）
• ギリアド・サイエンシズ（米国）
• シプラ社（米国）
• バウシュ・ヘルス・カンパニーズ（カナダ）
• オーロビンドファーマ（インド）
• ヘテロ（インド）
• テバ製薬工業株式会社（アイルランド）

SKU-59240